Untitled

White, Valerie A.; Esmaeli, Bita; Dutton, Jonathan J.; Heegaard, Steffen; Yin, Vivian T.; Sauerwein, W.; Coupland, Sarah E.; Finger, Paul T.

doi:10.1007/978-3-319-40618-3_69

Cited by 5 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All cases were histologically reviewed to confirm the diagnosis. Patient information was retrieved from patient files and staged accordingtotheAJCC8th edition (White et al 2017). The study adhered to the tenets of the Declaration of Helsinki and hasbeenapprovedbytheRegionalEthics Committee (Journal No.…”

Section: Patient Materialsmentioning

confidence: 99%

Recurrent rearrangements of the PLAG1 and HMGA2 genes in lacrimal gland pleomorphic adenoma and carcinoma ex pleomorphic adenoma

Andreasen

Holstein

Homøe

et al. 2018

Acta Ophthalmologica

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Patient Materialsmentioning

confidence: 99%

Recurrent rearrangements of the PLAG1 and HMGA2 genes in lacrimal gland pleomorphic adenoma and carcinoma ex pleomorphic adenoma

Andreasen

Holstein

Homøe

et al. 2018

Acta Ophthalmologica

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hence, radiation therapy has been used to extend surgical margins. 5,10 Orbital sebaceous carcinomas have been treated with EBRT doses of 45–63 Gy that typically exceed the tolerance of critical normal ocular structures leading to severe dry eye, conjunctival keratinization, keratopathy, cataracts, optic neuropathy, retinopathy, and loss of vision. Brachytherapy boost offers a method to improve orbital radiation dose distribution, increase the dose to the tumor bed while reducing dose to critical normal ocular structures.…”

Section: Discussionmentioning

confidence: 99%

“…Postoperative, total body positron-emission tomography/CT revealed no residual orbital carcinoma or systemic disease. 5 In an effort to treat presumed orbital microscopic disease, adjuvant radiation therapy was advised. The risks of potential benefits of sole external beam radiotherapy (EBRT) and combination brachytherapy-boost technique were discussed.…”

Section: Case Presentationmentioning

confidence: 99%

Interstitial Brachytherapy for Orbital Sebaceous Carcinoma

Stewart

Finger

2021

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Sebaceous carcinoma is characterized by its aggressive local tumor behavior and ability to metastasize. Small periocular sebaceous carcinoma are typically treated by excision with cryotherapy. Larger tumors often require adjuvant external beam radiotherapy (EBRT) and/or exenteration surgery. When used alone, EBRT techniques typically exceed the tolerance of critical normal ocular structures. The interstitial orbital brachytherapy-boost technique permits dose escalation to the tumor bed, while minimizing radiation dose to critical normal ocular structures. Here, we present a case of orbital sebaceous carcinoma treated with excision, cryotherapy, and super-thick amniotic membrane fornix reconstruction. Then, after 3 weeks of healing, adjuvant-combined electron interstitial high-dose rate brachytherapy-boost was added to electron-beam radiotherapy to optimize the orbital radiation dose distribution, increase dose to inferonasal orbit, and allow relative sparing of orbital tissues. At 1-year follow-up, there was no evidence of orbital tumor, no significant eye lash loss, normal ocular motility, no radiation retinopathy, optic neuropathy and a visual acuity of 20/20.

show abstract

“…4,5 Histological records and medical imaging were used to stage tumors according to the 8th edition of the American Joint Committee on Cancer (AJCC) classification. 6 Based on the WHO classification of salivary gland CXPA, the tumors were also classified as noninvasive (carcinoma in situ, intracapsular), minimally invasive (≤1.5 mm of capsule breach) and invasive (>1.5 mm beyond the capsule). 3 Except for 2 historic (pre-1992) cases undergoing cranioorbital resection (COR), all patients underwent local resection (macroscopically intact wherever possible) through an upper eyelid skin-crease incision.…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Carcinoma Expleomorphic Adenoma of the Lacrimal Gland

Vahdani

Rose

2021

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Aims: To report the characteristics and long-term outcomes of patients presenting with carcinoma ex-pleomorphic adenoma (CXPA) or malignant mixed tumor of the lacrimal gland. Methods: A retrospective case-note review for patients with CXPA, seen at Moorfields Eye Hospital between 1985 and 2018, was performed for demographics, presentation, imaging, histopathology, management, and outcome. Results: Twenty-six patients (11 male; 42%) presented at a mean age of 46 years (median 46.4; range 24–81), with average symptom(s) duration of 67 months (median 24 months; range 6 weeks–53 years). The commonest symptoms were proptosis (13 patients; 50%), orbital ache or pain (11/26, 42%), having noted a lump in the upper eyelid (8/26, 31%), and diplopia (7/26, 27%). About 90% of patients had nonaxial globe displacement, over a half had a palpable mass and 3-quarters had reduced motility. Adenocarcinoma was the commonest malignant component of the tumor, occurring in 16 (62%) of the patients, followed by adenoid cystic carcinoma in 5 patients (19%); 10/26 (28%) tumors showed significant invasion on histological examination. A quarter of the patients had tumor-related death at an average of 2.8 years after diagnosis (median 2.5; range 1.5–4.4 years), and the overall probability of survival for the whole cohort was 63% at both 5 years and 10 years after treatment. The prognosis for CXPA was significantly worse with a history of prior incompletely excised pleomorphic adenoma (p < 0.001), a markedly invasive malignant component (p = 0.001), evidence of perineural invasion (p = 0.042), and an American Joint Committee on Cancer tumor size of T3 or greater (p = 0.024). Conclusion: Intact excision of CXPAs that do not display histological evidence of extension beyond the tumor pseudocapsule have a good outcome, similar to that for intact excision of benign pleomorphic adenomas. In contrast, our patients with markedly invasive CXPA had a tendency to local recurrence or distant metastasis, and tumor-related death occurred in about two-thirds.

show abstract

Untitled

Cited by 5 publications

References 22 publications

Recurrent rearrangements of the PLAG1 and HMGA2 genes in lacrimal gland pleomorphic adenoma and carcinoma ex pleomorphic adenoma

Recurrent rearrangements of the PLAG1 and HMGA2 genes in lacrimal gland pleomorphic adenoma and carcinoma ex pleomorphic adenoma

Interstitial Brachytherapy for Orbital Sebaceous Carcinoma

Carcinoma Expleomorphic Adenoma of the Lacrimal Gland

Contact Info

Product

Resources

About